Genelux (NASDAQ:GNLX) Upgraded to Hold at Wall Street Zen

Genelux (NASDAQ:GNLX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research analysts also recently issued reports on GNLX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Lake Street Capital assumed coverage on shares of Genelux in a research note on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price target for the company. Maxim Group set a $20.00 price objective on shares of Genelux in a research report on Tuesday, October 21st. Finally, Loop Capital set a $16.00 target price on Genelux in a research report on Tuesday, October 21st. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Genelux Trading Up 4.4%

GNLX stock opened at $4.55 on Friday. The firm has a market cap of $173.13 million, a PE ratio of -5.17 and a beta of 0.17. The stock has a 50-day moving average price of $5.29 and a 200-day moving average price of $4.36. Genelux has a 1-year low of $1.99 and a 1-year high of $8.53.

Genelux (NASDAQ:GNLX) last announced its earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. On average, analysts forecast that Genelux will post -0.88 earnings per share for the current year.

Insider Activity at Genelux

In related news, Director John Thomas sold 10,000 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $5.00, for a total value of $50,000.00. Following the sale, the director owned 492,784 shares in the company, valued at $2,463,920. This represents a 1.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 15,990 shares of company stock worth $82,054 over the last ninety days. Insiders own 8.80% of the company’s stock.

Institutional Trading of Genelux

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning raised its stake in shares of Genelux by 4.7% in the third quarter. Creative Planning now owns 46,108 shares of the company’s stock worth $194,000 after purchasing an additional 2,084 shares during the last quarter. Raymond James Financial Inc. grew its holdings in Genelux by 22.6% during the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after buying an additional 5,333 shares in the last quarter. Geode Capital Management LLC grew its holdings in Genelux by 1.8% during the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after buying an additional 5,596 shares in the last quarter. 5T Wealth LLC raised its position in Genelux by 33.9% in the 3rd quarter. 5T Wealth LLC now owns 24,101 shares of the company’s stock valued at $101,000 after buying an additional 6,100 shares during the last quarter. Finally, LifeSteps Financial Inc. lifted its stake in Genelux by 8.2% during the 3rd quarter. LifeSteps Financial Inc. now owns 105,171 shares of the company’s stock valued at $442,000 after acquiring an additional 7,952 shares in the last quarter. 37.33% of the stock is owned by institutional investors.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.